HyperGam polyclonal antibody: NBIO completed the U.S.

NBIO expects European enrollment of 21 patients to be complete by the end of January. The trial will enroll a total of 173 patients.

Patients were randomized to receive either 200 or 400 mg/kg of HyperGam, a polyclonal antibody, or albumin placebo monthly iv for 12 months. The primary end point is a reduction in acute pulmonary exacerbations of infection. Secondary end points are the reduction of antibiotic use, and days lost from school or work. ...